MA51311A - Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées - Google Patents

Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées

Info

Publication number
MA51311A
MA51311A MA051311A MA51311A MA51311A MA 51311 A MA51311 A MA 51311A MA 051311 A MA051311 A MA 051311A MA 51311 A MA51311 A MA 51311A MA 51311 A MA51311 A MA 51311A
Authority
MA
Morocco
Prior art keywords
hbv
vaccines
hepatitis
virus
related uses
Prior art date
Application number
MA051311A
Other languages
English (en)
Inventor
Daniel Boden
Pooter Dorien De
Helen Horton
Jean-Marc Edmond Fernand Marie Neefs
Soumitra Roy
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA51311A publication Critical patent/MA51311A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA051311A 2017-12-19 2018-12-18 Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées MA51311A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607426P 2017-12-19 2017-12-19
IB2017058142 2017-12-19

Publications (1)

Publication Number Publication Date
MA51311A true MA51311A (fr) 2020-10-28

Family

ID=65199441

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051311A MA51311A (fr) 2017-12-19 2018-12-18 Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées

Country Status (15)

Country Link
EP (2) EP4272833A3 (fr)
JP (1) JP7317017B2 (fr)
KR (1) KR20200101416A (fr)
CN (1) CN111836641A (fr)
AU (1) AU2018389787A1 (fr)
BR (1) BR112020011976A2 (fr)
CA (1) CA3086327A1 (fr)
ES (1) ES2963179T3 (fr)
IL (1) IL275427B2 (fr)
JO (1) JOP20200153A1 (fr)
MA (1) MA51311A (fr)
MX (3) MX2020006480A (fr)
PH (1) PH12020550924A1 (fr)
SG (1) SG11202005895QA (fr)
WO (1) WO2019123252A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110073002B (zh) 2016-10-17 2024-06-11 杨森制药公司 重组病毒复制子体系及其用途
KR102655641B1 (ko) 2016-12-05 2024-04-05 얀센 파마슈티칼즈, 인코포레이티드 유전자 발현을 향상시키기 위한 조성물 및 방법
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
EP3740245A4 (fr) 2018-01-19 2022-01-05 Janssen Pharmaceuticals, Inc. Induction et amélioration des réponses immunitaires à l'aide de systèmes de réplicon de recombinaison
WO2020255018A1 (fr) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
US20220313815A1 (en) * 2019-06-20 2022-10-06 Janssen Sciences Ireland Unlimited Company Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof
WO2022133230A1 (fr) * 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
AU2022311974A1 (en) * 2021-07-16 2024-02-22 Mcmaster University Viral vaccine

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
CA2168583C (fr) * 1993-08-02 2007-10-02 Francis V. Chisari Peptides induisant des reactions cytotoxiques des lymphocytes t contre le virus de l'hepatite b
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
EA002087B1 (ru) 1997-04-03 2001-12-24 Электрофект Ас Способ введения фармацевтических препаратов и нуклеиновых кислот в скелетную мышцу
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
WO1999001158A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
AU770092B2 (en) 1998-07-13 2004-02-12 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
KR20030074787A (ko) * 2001-02-05 2003-09-19 스트레스젠 바이오테크놀러지스 코포레이션 Ｂ형 간염 바이러스 치료
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US9364664B2 (en) 2004-03-08 2016-06-14 Ichor Medical Systems, Inc. Apparatus for electrically mediated delivery of therapeutic agents
CN105457157B (zh) 2006-10-17 2020-04-14 因诺维奥制药公司 电穿孔装置及用其进行哺乳动物细胞电穿孔的方法
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
US8877205B2 (en) * 2011-02-12 2014-11-04 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis B infection
TWI575070B (zh) * 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
CA3018223A1 (fr) 2016-03-28 2017-10-05 Ichor Medical Systems, Inc. Procede et appareil permettant d'administrer des agents therapeutiques
CN118063563A (zh) * 2016-04-06 2024-05-24 华盛顿大学 用于乙型肝炎病毒（hbv）的使用hbv核心抗原的治疗性疫苗

Also Published As

Publication number Publication date
SG11202005895QA (en) 2020-07-29
JP7317017B2 (ja) 2023-07-28
WO2019123252A1 (fr) 2019-06-27
KR20200101416A (ko) 2020-08-27
AU2018389787A1 (en) 2020-06-25
EP4272833A2 (fr) 2023-11-08
IL275427A (en) 2020-08-31
PH12020550924A1 (en) 2021-05-31
BR112020011976A2 (pt) 2020-11-24
ES2963179T3 (es) 2024-03-25
IL275427B1 (en) 2023-12-01
EP3727445B1 (fr) 2023-08-16
EP4272833A3 (fr) 2024-01-10
EP3727445C0 (fr) 2023-08-16
CA3086327A1 (fr) 2019-06-27
JP2021509107A (ja) 2021-03-18
MX2020011802A (es) 2020-12-07
JOP20200153A1 (ar) 2022-10-30
EP3727445A1 (fr) 2020-10-28
MX2020006480A (es) 2020-09-22
CN111836641A (zh) 2020-10-27
MX2020011804A (es) 2020-12-07
IL275427B2 (en) 2024-04-01

Similar Documents

Publication Publication Date Title
MA51311A (fr) Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
MA50813A (fr) Vaccins contre le virus d'epstein-barr
MA49463A (fr) Vaccin contre le virus de l'herpès simplex
HK1248681A1 (zh) 作為hbsag(hbv表面抗原)和hbv dna生成的抑制劑用於治療乙型肝炎病毒感染的四氫吡啶並嘧啶和四氫吡啶並吡啶類化合物
HK1255502A1 (zh) B型肝炎病毒(hbv)irna組合物及其使用方法
MA50520A (fr) Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb)
EP3710049A4 (fr) Vaccin thérapeutique contre le virus de l'hépatite b (vhb) utilisant les régions pres1 et/ou pres2 et/ou s-hbsag du vhb de la protéine d'enveloppe du vhb
MA50524A (fr) Nouveaux indole-2-carboxamides à substitution amino-thiazole hautement actifs agissant contre le virus de l'hépatite b (vhb)
MA51292A (fr) Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb)
EP3439696A4 (fr) Vaccin thérapeutique contre le virus de l'hépatite b (vhb) utilisant l'antigène nucléocapsidique du vhb
MA51312A (fr) Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb)
HK1251010A1 (zh) 用於治療乙型肝炎病毒(hbv)感染的試劑及用途
IL273093A (en) Combination of drugs for the treatment of hepatitis B virus type HBV patients using Parafoxvirus Obis (PPVO) and at least one other antiviral agent
MA56535A (fr) Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
SG11201808266QA (en) Hepatitis b treatment vaccine on the basis of inactivated, fully recombinant hansenula cells expressing hbsag
MA56524A (fr) Vecteurs d'arénavirus pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
MA45994A (fr) Vaccins contre des virus
IL277128A (en) Hepatitis B vaccines and their uses
MA56533A (fr) Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof
WO2014160088A3 (fr) Traitement d'infections par le virus de l'hépatite b
EP3452595A4 (fr) Réactifs pour le traitement d'infection par le virus de l'hépatite b (vhb) et utilisation de ceux-ci
IL286484B (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
GB201702193D0 (en) Hepatitis E virus vaccine
PL3244921T3 (pl) Immunogenna szczepionka przeciwko wirusowi HCV i/lub HBV